51 phenotypes from 4 alleles in 5 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Socs2em1(IMPC)H/Socs2em1(IMPC)H C57BL/6NTac-Socs2em1(IMPC)H/H	decreased grip strength	J:211773
	increased circulating creatinine level	J:211773
	increased spleen weight	J:211773
Socs2m1Btlr/Socs2m1Btlr C57BL/6J-Socs2m1Btlr	increased body weight	J:221476
Socs2tm1Vem/Socs2tm1Vem involves: 129P2/OlaHsd * C57BL/6J	abnormal bone trabecula morphology	J:225936
	abnormal long bone epiphyseal plate proliferative zone	J:225936
	abnormal tibia morphology	J:225936
	decreased bone trabecular spacing	J:225936
	increased body weight	J:225936
	increased bone trabecula number	J:225936
	increased compact bone area	J:225936
	increased diameter of tibia	J:225936
	increased long bone epiphyseal plate size	J:225936
	increased trabecular bone thickness	J:225936
	increased trabecular bone volume	J:225936
	increased width of hypertrophic chondrocyte zone	J:225936
	long tibia	J:225936
	normal skeleton phenotype	J:225936
Socs2tm1Wehi/Socs2+ C57BL/6-Socs2tm1Wehi	increased body weight	J:63006
Socs2tm1Wehi/Socs2tm1Wehi C57BL/6-Socs2tm1Wehi	abnormal hepatobiliary system morphology	J:63006
	abnormal insulin-like growth factor I level	J:63006
	abnormal lung morphology	J:63006
	abnormal pancreatic duct morphology	J:63006
	abnormal salivary gland duct morphology	J:63006
	abnormal urine homeostasis	J:63006
	normal adipose tissue phenotype	J:63006
	increased body length	J:63006
	increased body weight	J:63006
	increased growth rate	J:63006
	increased length of long bones	J:63006
	long femur	J:63006
	long humerus	J:63006
	long radius	J:63006
	long tibia	J:63006
	thick dermal layer	J:63006
Socs2tm1Wehi/Socs2tm1Wehi involves: C57BL/6 * C57BL/6J	abnormal circulating cytokine level	J:186227
	abnormal circulating hormone level	J:186227
	abnormal glucose homeostasis	J:186227
	abnormal macrophage physiology	J:186227
	decreased circulating growth hormone level	J:186227
	decreased circulating insulin-like growth factor I level	J:186227
	decreased liver triglyceride level	J:186227
	decreased susceptibility to diet-induced hepatic steatosis	J:186227
	impaired glucose tolerance	J:186227
	increased circulating glucose level	J:186227
	increased circulating insulin level	J:186227
	increased circulating interferon-gamma level	J:186227
	increased circulating interleukin-1 beta level	J:186227
	increased interferon-gamma secretion	J:186227
	increased interleukin-1 beta secretion	J:186227
	increased renal fat pad weight	J:186227
	increased skeletal muscle triglyceride level	J:186227
	increased tumor necrosis factor secretion	J:186227
	insulin resistance	J:186227
	liver inflammation	J:186227